The economic benefit of implementing assisted reproductive technology within a national health system: insights from the Italian model

Andrea Marcellusi, Matteo Scortichini (), Giulio Guarnotta, Mark Connolly and Andrea Busnelli
Additional contact information
Andrea Marcellusi: University of Milan
Matteo Scortichini: University of Rome “Tor Vergata,”
Giulio Guarnotta: University of Rome “Tor Vergata,”
Mark Connolly: Health Economics, Global Market Access Solutions Sarl
Andrea Busnelli: Humanitas University

Health Economics Review, 2025, vol. 15, issue 1, 1-12

Abstract: Abstract Background Models evaluating both costs and economic benefits of assisted reproductive technology (ART) implementation are lacking. This constitutes a major limitation in the decision-making process of resource allocation. Herein, we aimed to estimate the economic and social impact of female infertility in Italy and examine the benefits generated by investment in ART from a national perspective. Methods A retrospective cohort study was conducted using the Italian Hospital Discharge Records database to identify women aged 18–50 undergoing ART between 2014 and 2016 in Italy. Patients were followed for up to 36 months after the first ART complete cycle. Hospitalization costs were analyzed nationally, while outpatient care and drug consumption costs were assessed in a sub-analysis using administrative databases from LHU Umbria 2. A fiscal impact model was developed from a governmental perspective, projecting lifetime tax revenues and public expenditures associated with the ART birth cohort, including costs for healthcare, education, pensions, and social transfers. All future values were discounted at 3% in line with Italian economic evaluation guidelines. Results A total of 33,713 women met the inclusion criteria. During the follow-up, 48.4% achieved pregnancy resulting in childbirth. The average hospital care cost per patient was €5,853, with a projected national expenditure of €337 million for ART management. Younger women (18–33 years) had the highest success rates (61.8%). Assuming 16,300 live births, the model estimated net fiscal benefits of €3.3 billion over the lifetime of these individuals, equivalent to €203,856 per live birth. Conclusion This study highlights the economic and fiscal benefits of ART, emphasizing the need for policies promoting early access to treatment. ART investment represents a strategic approach to mitigate demographic decline, with each live birth substantially contributing to national fiscal stability.

Keywords: Infertility; Assisted reproductive technology; Medically assisted reproduction; Real world evidence; Italy; Economic burden (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1186/s13561-025-00672-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:15:y:2025:i:1:d:10.1186_s13561-025-00672-1

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-025-00672-1

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().